reported that lenvatinib inhibited the FGFR4 signaling pathway, downregulated the expression of PD-L1 on tumor cells, and limited the differentiation of Tregs, thereby modulating the tumor immune microenvironment to enhance the efficacy of PD-1 (40). Here, CD274 is linked to neoplasm.